Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 19 recruiting now early-phase tilt

Seizures: early-phase trial registry

19 of 40 indexed Seizures trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #368 of 28,707 conditions by registered trial count.

40 US clinical trials · 19 currently recruiting · #368 of 28,707 conditions by registered trial count

Seizures: 40 US clinical trials tracked, 19 recruiting.

Seizures is the subject of 40 registered US clinical trials on ClinicalTrials.gov, 19 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Neurological Disorders and Stroke (NINDS), running 4 of these trials.

Enrollment posture brief

Registry condition seizures

OPEN 19 | RECR 48% | LATE 6 | EARLY 13 | RANK #368 | SPON 4

Nearest open-share peer: Metastatic Lung Non-Small Cell Carcinoma (48% recruiting · 40 trials)

Seizures (this)48%Anatomic Stage IIIA Breast C35%Human Immunodeficiency Virus30%Heart Failure, Congestive12.5%Cocaine Dependence7.5%
Open-enrollment share among volume-matched conditions near Seizures

Seizures lists 19 open slots (48% of 40 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Seizures on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Seizures is recruiting above its size-band peers.

    19 of 40 indexed trials (47.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Seizures trials is spread across many organizations.

    National Institute of Neurological Disorders and Stroke (NINDS) accounts for 4 of 40 trials (10%). 32 distinct sponsors appear on at least one study for this condition label.

  3. Typical Seizures enrolment sits around 65 participants.

    Median target enrolment is 65 among the 40 trials that report a genuine target (sentinel values excluded). 22 of those (55%) plan for fewer than 100 participants.

  4. Seizures splits between interventional and observational designs.

    27 interventional and 13 observational studies make up this index (67.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 16Phase 27Phase 36

Open and recent trials

40 total, page 1 of 1

RECRUITING 20,000 participants

De-identified UNMH EEG Corpus Database Creation With Fully De-identified Clinical Information

University of New Mexi

NCT05140265

RECRUITING Phase 3 6,700 participants

Pediatric Dose Optimization for Seizures in Emergency Medical Services

Stanford University

NCT05121324

RECRUITING 2,500 participants

Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children

Children's Hospital of Philadelphia

NCT03419260

RECRUITING 1,000 participants

Longitudinal Study of Neurogenetic Disorders

Columbia University

NCT03492060

RECRUITING 1,000 participants

Investigating Epilepsy: Screening and Evaluation

National Institute of Neurological Disorders and Stroke (NINDS)

NCT03478852

RECRUITING 600 participants

Genetic Markers of Cardiovascular Disease in Epilepsy

Mayo Clinic

NCT02824822

RECRUITING NA 400 participants

Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy

University of Florida

NCT02216500

RECRUITING Phase 3 252 participants

Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

SK Life Science

NCT05219617

RECRUITING NA 190 participants

Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy

Neuroelectrics Corporation

NCT04770337

RECRUITING Phase 2 150 participants

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Ayal A. Aizer, MD

NCT07130786

RECRUITING NA 65 participants

Impact of Capturing Ictal Events With Ultra-long-term Ambulatory EEG Monitoring With Remote EEG Monitoring System.

Epitel

NCT06027749

RECRUITING NA 62 participants

Oxygen Toxicity: Mechanisms in Humans

Duke University

NCT05761756

RECRUITING Early Phase 1 60 participants

Pharmacological Modulation of Brain Oscillations in Memory Processing

University of Texas Southwestern Medical Center

NCT05594017

RECRUITING Phase 2 52 participants

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

University of California, San Francisco

NCT06401707

RECRUITING NA 40 participants

Ear-Seizure Detection (EarSD) Study

Felicia Chu

NCT06598189

RECRUITING NA 30 participants

Modulating Movement Intention Via Cortical Stimulation

NYU Langone Health

NCT03233399

RECRUITING Phase 2 30 participants

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

University of California, San Francisco

NCT05851391

RECRUITING NA 25 participants

Glioblastoma Remote Monitoring and Care - Research Protocol

Case Comprehensive Cancer Center

NCT06129760

RECRUITING NA 10 participants

Acute Effects of Focused Ultrasound Modulation on EEG Behavior in Status Epilepticus Patients

Yale University

NCT05784805

ACTIVE NOT RECRUITING 39 participants

Neural Circulatory Control and SUDEP Risk.

Mayo Clinic

NCT02813980

ACTIVE NOT RECRUITING Phase 2 24 participants

RNS System LGS Feasibility Study

NeuroPace

NCT05339126

ACTIVE NOT RECRUITING Phase 1 5 participants

BHV-7000 Responsive Neurostimulation System (RNS) Study

Yale University

NCT07125261

COMPLETED Phase 3 720 participants

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

US Department of Veterans Affairs

NCT00007670

COMPLETED Phase 3 453 participants

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

Children's Hospital Medical Center, Cincinnati

NCT00088452

COMPLETED Phase 2 358 participants

Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures

University of Utah

NCT00326612

COMPLETED Phase 3 306 participants

Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

GlaxoSmithKline

NCT00232596

COMPLETED 300 participants

Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia

Vidya Raman

NCT01897974

COMPLETED Phase 2 274 participants

Hypovitaminosis D in Neurocritical Patients

University of Utah

NCT02881957

COMPLETED Phase 3 238 participants

Clobazam in Patients With Lennox-Gastaut Syndrome

Lundbeck

NCT00518713

COMPLETED 185 participants

Search for Genes Influencing Childhood Absence Epilepsy (CAE) Study

Icahn School of Medicine at Mount Sinai

NCT00041951

COMPLETED 80 participants

Metabolic Abnormalities in Children With Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00001325

COMPLETED Phase 1 61 participants

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

INSYS Therapeutics

NCT02324673

COMPLETED Phase 1 59 participants

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions

Roxane Laboratories

NCT01703468

COMPLETED 40 participants

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

Beth Israel Deaconess Medical Center

NCT03103425

COMPLETED Phase 1 39 participants

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

U.S. Army Office of the Surgeon General

NCT00534378

COMPLETED 34 participants

Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene

Children's Hospital Medical Center, Cincinnati

NCT03892798

COMPLETED 32 participants

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

National Institute of Neurological Disorders and Stroke (NINDS)

NCT00001666

COMPLETED Phase 2 19 participants

Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency

National Institute of Neurological Disorders and Stroke (NINDS)

NCT02019667

COMPLETED Phase 1 12 participants

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Dana-Farber Cancer Institute

NCT04497142

COMPLETED 6 participants

Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00001912

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 7
Phase 3 6

Named interventions

Most-linked intervention names on Seizures records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
5 trials
Perampanel Drug
2 trials
Lamotrigine Drug
2 trials
Midazolam Drug
2 trials
Retigabine Drug
1 trials
Valproic acid Drug
1 trials
Ethosuximide Drug
1 trials
No interventions are planned Other
1 trials

US sites by state

Facility locations filed on Seizures trials. A trial with sites in several states counts in each.

California 11 trials
New York 10 trials
Maryland 10 trials
Florida 9 trials
Massachusetts 8 trials
Texas 6 trials
Pennsylvania 6 trials
Minnesota 6 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Seizures page

40 registered trials, 19 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Seizures condition card totals 40 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.